Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review

Penson, Peter E.; Șerban, Maria-Corina; Ursoniu, Sorin; Banach, Maciej

doi:10.1080/10408398.2016.1272045

Cited by 21 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the prioritized dietary variables, boiled (unfiltered) coffee but not brewed (filtered) coffee was found positively associated with lipid traits, specifically with total cholesterol, triglycerides, and LDL cholesterol. Previous metanalyses have also identified associations between unfiltered coffee and dose-dependent increase of plasma concentrations of total and LDL cholesterol (25, 26). The effects of coffee in the lipid profile are probably caused by two diterpenes (i.e.…”

Section: Discussionmentioning

confidence: 94%

Environment-wide association study (EWAS) on cardiometabolic traits: A systematic assessment of the association of lifestyle variables on a longitudinal setting

Poveda

Chen

Pomares-Millan

et al. 2021

Preprint

View full text Add to dashboard Cite

The present study aims to assess the over-time association of ~300 lifestyle exposures with nine cardiometabolic traits with the ultimate aim of identifying exposures/exposure groups that could inform lifestyle interventions aiming at controlling cardiometabolic diseases. The analyses were undertaken in a longitudinal sample comprising >31000 adults living in northern Sweden. Linear mixed models were used to assess the average associations of lifestyle exposures and linear regression models were used to test association with 10-year change of the cardiometabolic traits. "Physical activity" and "General Health" were the exposure categories containing the highest number of "tentative signals" in analyses assessing the average association of lifestyle variables, while "Tobacco use" was the top-category for the 10-year change association analyses. Thirteen modifiable variables showed a consistent average association among the majority of cardiometabolic traits. These variables belonged to four main groups: i) Smoking, ii) Diet (secoisolariciresinol intake and brewed coffee), iii) Leisure time physical activity and iv) a group of variables more specific to the Swedish lifestyle (snuff status, hunting/fishing during leisure time and boiled coffee). Interestingly, sweet drinks, fish intake and salt content, all lifestyle exposures frequently mentioned in public health recommendations were not broadly associated with the analysed cardiometabolic traits.

show abstract

Section: Discussionmentioning

confidence: 94%

Environment-wide association study (EWAS) on cardiometabolic traits: A systematic assessment of the association of lifestyle variables on a longitudinal setting

Poveda

Chen

Pomares-Millan

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Different findings might be explained by different processing methods used for preparation of coffee. In a systematic review, Penson et al reported that the type of coffee and the methods of preparation are important for the effect of coffee consumption on serum levels of lipoproteins [53]. In addition, different duration of intervention, recruiting participants with different health conditions and different quality of clinical trials are other reasons for the observed discrepancy across clinical trials investigating the effects of coffee consumption on TC levels.…”

Section: Discussionmentioning

confidence: 99%

The effects of green coffee extract supplementation on glycemic indices and lipid profile in adults: a systematic review and dose-response meta-analysis of clinical trials

Asbaghi

Sadeghian

Nasiri

et al. 2020

Nutr J

View full text Add to dashboard Cite

Background: The role of coffee consumption in the risk of cardiovascular diseases has been debated for many years. The current study aimed to summarize earlier evidence on the effects of green coffee extract (GCE) supplementation on glycemic indices and lipid profile. Methods: We searched available online databases for relevant clinical trials published up to October 2019. All clinical trials investigating the effect of GCE supplementation, compared with a control group, on fasting blood glucose (FBG), serum insulin, total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were included. Overall, 14 clinical trials with a total sample size of 766 participants were included in the current meta-analysis. Results: We found a significant reducing effect of GCE supplementation on FBG (weighted mean difference (WMD):-2.35, 95% CI: − 3.78, − 0.92 mg/dL, P = 0.001) and serum insulin (WMD:-0.63, 95% CI: − 1.11, − 0.15 μU/L, P = 0.01). With regard to lipid profile, we observed a significant reduction only in serum levels of TC following GCE supplementation in the overall meta-analysis (WMD:-4.51, 95% CI: − 8.39, − 0.64, P = 0.02). However, subgroup analysis showed a significant reduction in serum TG in studies enrolled both genders. Also, such a significant reduction was seen in serum levels of LDL and HDL when the analyses confined to studies with intervention duration of ≥8 weeks and those included female subjects. In the non-linear dose-response analyses, we found that the effects of chlorogenic acid (CGA) dosage, the main polyphenol in GCE, on FBG, TG and HDL were in the nonlinear fashions.

show abstract

“…Lipoprotein(a) (Lp(a)) is another relatively neglected lipoprotein which is both thrombogenic and atherogenic and which confers considerable risk of ASCVD when elevated [ 38 , 39 ]. Circulating concentrations of Lp(a) are largely genetically determined; however, dietary and nutraceutical approaches to Lp(a)-lowering including l -carnitine and coenzyme Q10 have been evaluated and shown promise in clinical and experimental studies [ 40 , 41 ]. If nutraceutical approaches to Lp(a) are shown to be effective in RCTs, the resulting products could serve an important role in optimizing lipid-lowering therapy in individuals at high risk of ASCVD.…”

Section: Nutraceuticals To Manage Residual Risk Associated With Lipidmentioning

confidence: 99%

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia

Penson

Banach

2020

Curr Atheroscler Rep

Self Cite

View full text Add to dashboard Cite

Purpose of Review We aimed to summarize recent guidelines, position papers, and high-quality clinical research relating the use of nutraceuticals in the management of individuals at high risk of atherosclerotic cardiovascular disease. Recent Findings It is essential that individuals at high risk of cardiovascular disease receive guideline-directed evidence-based therapies to reduce their risk of morbidity and mortality from cardiovascular events. Compared with conventional therapeutics, nutraceuticals have undergone relatively little investigation in randomized controlled trials. Thus, recommendations for nutraceuticals in international guidelines are rare, and nutraceuticals should not be used preferentially in place of statins. Nevertheless, recent position papers from the International Lipid Expert Panel and clinical evidence from studies of triglyceride reduction by polyunsaturated fatty acid administration demonstrate that nutraceuticals do have an important role in optimizing therapy in individuals at high risk of cardiovascular disease. Roles for nutraceuticals include as follows: (1) managing residual risk associated with lipids other than low-density lipoprotein cholesterol (LDL-C); (2) managing non-lipid-mediated residual risk; (3) optimizing LDL-C treatment in statin intolerance; (4) optimizing LCL-C treatment when add-on therapies for statins are not available; (5) as adjuncts to lifestyle for individuals at high lifetime risk of atherosclerotic cardiovascular disease (ASCVD). The strength of evidence for each of these applications is variable. Summary In addition to guideline-directed therapeutics, nutraceuticals may have roles in optimizing preventative therapy and targeting residual risk in individuals at high risk of ASCVD. Application of Good Manufacturing Practice and randomized controlled trials when producing and evaluating nutraceuticals will expand the armoury of evidence-based agents for the prevention of ASCVD.

show abstract

Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review

Cited by 21 publications

References 23 publications

Environment-wide association study (EWAS) on cardiometabolic traits: A systematic assessment of the association of lifestyle variables on a longitudinal setting

Environment-wide association study (EWAS) on cardiometabolic traits: A systematic assessment of the association of lifestyle variables on a longitudinal setting

The effects of green coffee extract supplementation on glycemic indices and lipid profile in adults: a systematic review and dose-response meta-analysis of clinical trials

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia

Contact Info

Product

Resources

About